

**APCCC Detailed Programme 2019 (subject to minor changes)**

**Areas of controversy**

1. Locally advanced prostate cancer (APC)
2. Biochemical recurrence of prostate cancer after local therapy
3. Management of the primary tumour in the metastatic setting
4. Newly diagnosed, castration-sensitive/naïve prostate cancer (CNPC), including oligometastatic prostate cancer
5. Management of nmCRPC (M0 CRPC)
6. Management of mCRPC
7. Bone and bone metastases
8. Molecular characterization: tissue and blood
9. Heterogeneity of patients with prostate cancer (ethnicity, elderly)
10. Side effects of hormonal treatments and their management

**Thursday 29<sup>th</sup> August 2019**

<b>Time</b>	<b>Session</b>	
<b>09:00</b>	<b>Welcome Address</b> Silke Gillissen and Aurelius Omlin on behalf of APCCC	
<b>09:15 – 10:45</b>	<b>Molecular biomarkers and novel imaging in APC</b>	<b>Chairs:</b> Bristow, Padhani, Gleave
<b>Session 1</b>		
9:15	<b>State of the art on molecular characterization in advanced prostate cancer (APC)</b> <ul style="list-style-type: none"> <li>- Non-metastatic prostate cancer</li> <li>- Metastatic castration-naïve</li> <li>- Metastatic CRPC</li> </ul>	Pritchard
9:30	<b>Clinical utility of molecular markers</b>	De Bono
9:45	<b>Which men need genetic counselling and/or testing?</b>	Eeles
10:00	<b>Discussion</b>	
10:15 10:25	<b>Advantages and pitfalls of PSMA PET/CT in APC imaging</b> <ul style="list-style-type: none"> <li>• Advantages</li> <li>• Pitfalls</li> </ul>	Fanti Davis
10:35	<b>Discussion</b>	
<b>10:45 – 11:15</b>	<b>COFFEE BREAK</b>	
<b>11:15 – 12:45</b>	<b>Node-positive prostate cancer (N1 but M0)</b>	<b>Chairs:</b> Feng, Briganti, Higano
<b>Session 2</b>		
<b>How to treat men with newly diagnosed cN1 cM0</b> a) based on classical imaging b) based on novel (next-generation) imaging		
11:15	<ul style="list-style-type: none"> <li>• <b>Surgery options</b></li> </ul>	Murphy
11:27	<ul style="list-style-type: none"> <li>• <b>Radiation therapy options</b></li> </ul>	Roach
11:39	<ul style="list-style-type: none"> <li>• <b>Systemic therapy options</b></li> </ul>	James
11:51	<b>Synthesis – How best to treat cN1 prostate cancer</b>	Fizazi
12:01	<b>Discussion</b>	
12:16	<b>How to treat men with pathological node positive (pN1, cM0) prostate cancer?</b>	Bossi
12:28	<b>Discussion</b>	
<b>12:45 – 13.45</b>	<b>LUNCH</b>	

<b>13:45 – 15:15</b> <b>Session 3</b>	<b>PSA recurrence after radical local therapy and oligometastatic prostate cancer</b>	<b>Chairs:</b> Khauli, Murthy, Zapatero
13:45	Management of men with PSA recurrence after radical local radiation therapy	Feng
13:57	Management of men with PSA recurrence or persistence after prostatectomy	Evans
14:09	<b>Discussion</b>	
14:20	Oligometastatic prostate cancer – Definitions and concepts	Reiter
14:30	Treatment of <u>de novo</u> (synchronous) oligometastatic prostate cancer	Morris
14:40	Treatment of <u>oligorecurrent</u> (metachronous) prostate cancer after local therapy	Ost
14:50	Treatment of oligometastatic and oligoprogressive CRPC)	Small
15:00	<b>Discussion</b>	
<b>15:15 – 15:45</b>	<b>COFFEE BREAK</b>	
<b>15:45 – 17:15</b> <b>Session 4</b>	<b>Regional care (demographic and environmental factors)</b>	<b>Chairs:</b> Halabi, Kanesvaran, Suzuki
15:45	Ethnicity and prognosis	Logothetis
16:00	Pharmaco-ethnicity and impact on treatment	Poon
16:15	Report and lessons learned from the consensus conference for developing countries	Maluf
16:30	Disparities in prostate cancer management in the U.S.	Morgans
16:45	The ageing population: Oncogeriatric assessment and treatment considerations	O'Sullivan
17:00	<b>Discussion</b>	

<b>Friday 30<sup>th</sup> August 2019</b>		
<b>Extra session 08:00 – 08:30</b>	<b>Movember Session</b>	<b>Chair:</b> Villanti
8:00	Outcomes Research – Ironman project	Morgans, Davis
8:20	<b>Discussion</b>	
<b>08:30 – 10:15 Session 5</b>	<b>Management of metastatic castration-sensitive/naive prostate cancer</b>	<b>Chairs:</b> Attard, Mottet
8:30	Testosterone measurement – Which test and when?	Gleave
8:40	Local treatment of the primary tumour (RT) in the metastatic situation	Bristow
8:50	Local treatment of the primary tumour (surgery) in the metastatic situation	Steuber
9:00	<b>Discussion</b>	
9:10	Which systemic therapy for which patient with newly diagnosed metastatic prostate cancer?	Sweeney
9:25	Addition of AR pathway inhibitors vs. docetaxel: Statisticians' perspective	Sydes
9:35	Synthesis – Optimal treatment of men with newly diagnosed metastatic prostate cancer	Clarke
9:45	Follow-up on ADT alone vs. ADT “plus”	Oh
9:55	<b>Discussion</b>	
<b>10:15 – 10:45</b>	<b>COFFEE BREAK</b>	
<b>10:45 – 12:45 Session 6</b>	<b>Management of castration-resistant prostate cancer (CRPC)</b>	<b>Chairs:</b> Sternberg, Duran
10:45	Definition and overview of treatment options in nmCRPC	Scher
10:55 11:03	<b>Debate: Treatment of nmCRPC</b> <ul style="list-style-type: none"> <li>• Pros</li> <li>• Cons</li> </ul>	Hussain Higano
11:11	First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor	Taplin
11:23	Subgroup analysis of mCRPC clinical trials	Halabi
11:33	<b>Discussion</b>	
11:45	PSMA targeted therapies	Hofman
11:57	Immunotherapy	Drake
12:09	PARP inhibition	Chi
12:21	Neuroendocrine spectrum: Diagnosis and treatment	Efstathiou
12:33	<b>Discussion</b>	
<b>12:45 – 13:45</b>	<b>LUNCH</b>	

<b>13:45 – 14:45</b> <b>Session 7</b>	<b>Side effects of treatment and their management</b>	<b>Chairs:</b> Bjartell, Leibowitz
13:45	<b>Management of sexuality and incontinence issues in APC</b>	Van Oort
13:55	<b>Management of hot flushes</b>	Frydenberg
14:05	<b>Management of metabolic changes</b>	Shore
14:15	<b>Management of fatigue, cognition/dementia</b>	Ryan
14:25	<b>Optimal steroid use with abiraterone</b>	Attard
14:35	<b>Discussion</b>	
<b>14:45 – 15:15</b>	<b>COFFEE BREAK</b>	
<b>15:15 – 16:45</b> <b>Session 8</b>	<b>Bone and bone metastases</b>	<b>Chairs:</b> Heinrich, Türkeri
15:15	<b>Prevention/Treatment of osteoporosis</b>	Saad
<b>Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC</b>		
15:30	<ul style="list-style-type: none"> <li>• Only for very select men with CRPC and bone metastases</li> </ul>	Parker
15:40	<ul style="list-style-type: none"> <li>• For the majority of men with CRPC and bone metastases</li> </ul>	Tombal
15:50	<ul style="list-style-type: none"> <li>• Synthesis – Best use of antiresorptive therapy in CRPC</li> </ul>	Smith
15:58	<b>Discussion</b>	
16:10	<b>Radium-223 and bone health agents</b>	Sartor
16:25	<b>The flare phenomenon in bone-metastatic APC</b>	Padhani
16:35	<b>Discussion</b>	
<b>16:45 – 17:15</b>	<b>COFFEE BREAK</b>	
<b>17:15 – 18:15</b> <b>Session 9</b>	<b>The future of APC management:</b>	<b>Chair:</b> Sade, Mrabti, Soule
17:15	<b>Wishes from a patient's perspective</b>	Millman
17:23	<b>In locally advanced prostate cancer</b>	Briganti
17:31	<b>In oligometastatic prostate cancer</b>	Beltran
17:39	<b>In polymetastatic prostate cancer</b>	Oh
17:47	<b>In imaging</b>	Fanti
17:55	<b>In biomarkers</b>	Rubin
18:03	<b>Global access to treatments</b>	Fizazi
18:11	<b>Discussion</b>	

<b>Saturday 31<sup>st</sup> of August 2019</b>		
<b>08:30 – 13:00</b> Special Session	All participants will be able to attend the panel meeting as part of the conference.	<b>Speakers</b>
08:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	<b>ALL PANEL MEMBERS</b> <b>Moderation:</b> Small and Tombal
<b>10:30 – 11:00</b>	<b>COFFEE BREAK</b>	
11:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	<b>ALL PANEL MEMBERS</b> <b>Moderation:</b> Small and Tombal
13:00	<b>Closing Remarks: S.Gillesen and A.Omlin</b>	